Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.
Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
This study evaluates the addition melatonin and metformin to conventional chemotherapy FDC
(Fluoruracil, Doxorubicin, cyclophosphamide) in the treatment of locally advanced breast
cancer. Third of patients will receive FDCх6 cycles, other third will receive combination of
melatonin and FDCх6 cycles and other patients will receive combination of metformin and FDCх6
cycles.
Phase:
Phase 2
Details
Lead Sponsor:
N.N. Petrov National Medical Research Center of Oncology Petrov Research Institute of Oncology